37.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$36.91
Offen:
$37.2
24-Stunden-Volumen:
930.19K
Relative Volume:
1.01
Marktkapitalisierung:
$3.22B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-5.7442
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
+9.21%
1M Leistung:
+6.00%
6M Leistung:
-24.74%
1J Leistung:
-11.02%
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RARE
Ultragenyx Pharmaceutical Inc
|
37.16 | 3.22B | 522.75M | -558.99M | -439.53M | -6.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-28 | Eingeleitet | William Blair | Outperform |
2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
2021-08-19 | Eingeleitet | UBS | Sell |
2021-07-15 | Eingeleitet | Guggenheim | Neutral |
2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
2021-03-02 | Fortgesetzt | Stifel | Buy |
2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
2019-08-02 | Fortgesetzt | Wedbush | Outperform |
2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-02-22 | Fortgesetzt | Raymond James | Outperform |
2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
2018-05-10 | Eingeleitet | Goldman | Neutral |
2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
2018-02-21 | Bestätigt | Stifel | Buy |
2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
2017-12-05 | Bestätigt | Barclays | Equal Weight |
2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com
How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com
Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq
Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN
William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus
William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com
William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com
Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus
Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan
Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN
Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus
(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmace - GuruFocus
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmaceutical | RARE Stock News - GuruFocus
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y - MSN
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Ultragenyx to Participate at Bank of America's 2025 Healthcare C - GuruFocus
Ultragenyx price target lowered to $100 from $140 at Truist - Yahoo Finance
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being - simplywall.st
Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Decoding Ultragenyx Pharmaceutical Inc (RARE): A Strategic SWOT Insight - GuruFocus
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ultragenyx Pharmaceutical Inc-Aktie (RARE) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Crombez Eric | EVP and Chief Medical Officer |
Apr 21 '25 |
Sale |
35.11 |
242 |
8,497 |
71,680 |
Horn Howard | Chief Financial Officer |
Mar 06 '25 |
Sale |
40.40 |
1,785 |
72,114 |
106,169 |
Kassberg Thomas Richard | CBO & EVP |
Mar 03 '25 |
Sale |
42.10 |
6,028 |
253,779 |
265,238 |
Parschauer Karah Herdman | EVP and Chief Legal Officer |
Mar 03 '25 |
Sale |
42.10 |
12,846 |
540,817 |
75,287 |
Crombez Eric | EVP and Chief Medical Officer |
Mar 03 '25 |
Sale |
42.10 |
8,945 |
376,584 |
71,922 |
Pinion John Richard | See Remarks |
Mar 03 '25 |
Sale |
42.10 |
14,439 |
607,882 |
107,766 |
KAKKIS EMIL D | President & CEO |
Mar 03 '25 |
Sale |
42.10 |
73,434 |
3,091,571 |
641,731 |
KAKKIS EMIL D | President & CEO |
Feb 28 '25 |
Sale |
42.48 |
25,000 |
1,062,000 |
2,158,985 |
Harris Erik | EVP & Chief Commercial Officer |
Mar 03 '25 |
Sale |
42.10 |
15,103 |
635,836 |
87,855 |
Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Mar 03 '25 |
Sale |
42.10 |
967 |
40,711 |
50,265 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):